WiSE® technology will be the protagonist of the next scientific session of the APHRS

SUNNYVALE, Calif., November 17, 2022 /PRNewswire/ — EBR Systems, Inc. (ASX: “EBR”, “EBR systems”or the “Agency”), developer of the world’s only wireless cardiac pacing system for heart failure, is pleased to announce that the company’s WiSE® technology will be the protagonist on the 15thth Asia Pacific Heart Rhythm Society (APHRS) Scientific Session in Singapore from 18th to 20th of November.

The APHRS is a leading non-profit organization representing medical, health care and scientific professionals specializing in heart rhythm disorders in the Asia-Pacific region. The annual conference is a world-class event featuring industry workshops and a core science agenda delivered by international and regional speakers.

Five abstracts with WiSE® were accepted for presentations, highlighting the technology’s position at the cutting edge of innovation in the cardiac rhythm management landscape. Abstract with WiSE® at the APHRS Scientific Session include the following:

  • Carry out cardiac resynchronization using WiSE® – Does leadless CRT pacing result in more QRS shortening than conventional resynchronization? – Dr Simon James (James Cook University Hospital, UK)

  • Feasibility of fully leadless CRT with leadless pacemaker and LV leadless endocardial pacing system – prof Pascal Defaye (Grenoble Alpes University Hospital, France)

  • Unleaded left bundle branch area stimulation: a feasibility study – Dr Mark Elliott (St Thomas’s Hospital, UK)

  • The effect of electrode placement on battery longevity during lead-free left ventricular endocardial pacing – Dr Mark Elliott (St Thomas’s Hospital, UK)

  • The first totally lead-free CRT system in the United States – Dr Dinesha Sharma (NCH Heart Institute, United States of America)

John McCutcheonPresident and CEO of EBR Systems said:
“We are excited to see our WiSE® System continues to be present at major conferences around the world. The abstracts presented in this scientific session strengthen the body of data supporting WiSE® while promoting our technology to a broad audience, including industry partners and the wider scientific community.”

About EBR Systems (ASX: EBR)

Silicon Valley-based EBR Systems (ASX: EBR) are dedicated to the superior treatment of heart rhythm diseases by providing more physiologically effective pacing through wireless cardiac pacing. Proprietary patented Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically a major source of complications and reliability issues in the management of heart rhythm disease. The initial product is designed to eliminate the need for coronary sinus leads to pace the left ventricle in heart failure patients requiring cardiac resynchronization therapy (CRT). Future products potentially address wireless endocardial pacing for bradycardia and other non-cardiac indications.

WiSE® technology from EBR Systems

EBR Systems’ WiSE technology is the world’s only wireless (in-the-heart) endocardial pacing system in clinical use to pace the left ventricle of the heart. This has long been a focus of cardiac pacing companies as left ventricular internal pacing is believed to be a potentially superior and more anatomically correct pacing position. WiSE technology enables cardiac pacing of the left ventricle with a new cardiac implant that is approximately the size of a large grain of rice. The need for a pacing lead outside the heart’s left ventricle – and associated problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the United States.

SOURCE EBR Systems

Leave a Reply

Your email address will not be published. Required fields are marked *